Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Are Bullish on Top Healthcare Stocks: HeartBeam (BEAT), Cresco Labs (CRLBF)

Tipranks - Fri Mar 6, 12:54PM CST

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on HeartBeam (BEATResearch Report) and Cresco Labs (CRLBFResearch Report) with bullish sentiments.

Claim 70% Off TipRanks Premium

HeartBeam (BEAT)

In a report released today, Kyle Bauser from Roth MKM maintained a Buy rating on HeartBeam, with a price target of $4.00. The company’s shares closed last Thursday at $1.42.

According to TipRanks.com, Bauser has 0 stars on 0-5 stars ranking scale with an average return of -12.4% and a 36.7% success rate. Bauser covers the Healthcare sector, focusing on stocks such as ARS Pharmaceuticals, InfuSystem Holdings, and Lemaitre Vascular. ;'>

Currently, the analyst consensus on HeartBeam is a Strong Buy with an average price target of $5.83, implying a 269.0% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $5.50 price target.

See the top stocks recommended by analysts >>

Cresco Labs (CRLBF)

In a report released today, Neal Gilmer from Haywood reiterated a Buy rating on Cresco Labs, with a price target of C$2.00. The company’s shares closed last Thursday at $0.94.

According to TipRanks.com, Gilmer has 0 stars on 0-5 stars ranking scale with an average return of -3.6% and a 38.8% success rate. Gilmer covers the Healthcare sector, focusing on stocks such as Green Thumb Industries, Auxly Cannabis Group, and Organigram Global. ;'>

The word on The Street in general, suggests a Hold analyst consensus rating for Cresco Labs.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.